These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27296043)

  • 21. Type 2 diabetes mellitus.
    DeFronzo RA; Ferrannini E; Groop L; Henry RR; Herman WH; Holst JJ; Hu FB; Kahn CR; Raz I; Shulman GI; Simonson DC; Testa MA; Weiss R
    Nat Rev Dis Primers; 2015 Jul; 1():15019. PubMed ID: 27189025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade.
    Xu Q; Wang L; Luo J; Shi D
    Curr Drug Targets; 2018; 19(1):55-69. PubMed ID: 28270085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.
    Xiang AH; Peters RK; Kjos SL; Goico J; Ochoa C; Marroquin A; Tan S; Hodis HN; Azen SP; Buchanan TA
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2846-51. PubMed ID: 15181067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the liver on post-prandial glycaemia--emphasis on hepatic glucose uptake.
    Kawamori R
    Int J Clin Pract Suppl; 2000 Sep; (112):19-22. PubMed ID: 11064947
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
    Giorgino F; Laviola L; Leonardini A
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S22-9. PubMed ID: 15955371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities.
    Tabatabaei-Malazy O; Nikfar S; Larijani B; Abdollahi M
    Expert Opin Pharmacother; 2016 Dec; 17(18):2449-2460. PubMed ID: 27819155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isosteviol increases insulin sensitivity and changes gene expression of key insulin regulatory genes and transcription factors in islets of the diabetic KKAy mouse.
    Nordentoft I; Jeppesen PB; Hong J; Abudula R; Hermansen K
    Diabetes Obes Metab; 2008 Sep; 10(10):939-49. PubMed ID: 18201205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does insulin preserve beta-cell function in type 2 diabetes?
    Heise T; Sawicki PT
    J Intern Med; 2002 Apr; 251(4):283-5. PubMed ID: 11952878
    [No Abstract]   [Full Text] [Related]  

  • 33. The introduction of insulin in type 2 diabetes mellitus.
    Wong J; Tabet E
    Aust Fam Physician; 2015 May; 44(5):278-83. PubMed ID: 26042399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing the insulin secretion defect: a logical first-line approach.
    Gerich JE
    Metabolism; 2000 Oct; 49(10 Suppl 2):12-6. PubMed ID: 11078470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R; Johnson DG
    Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Characteristics of the sensitivity of the pancreatic beta cells to arginine and glucose in patients with type-2 diabetes mellitus].
    Balabolkin MI; Gus MI; Kallikorm AP
    Probl Endokrinol (Mosk); 1986; 32(1):25-8. PubMed ID: 3081885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
    Korytkowski MT
    Pharmacotherapy; 2004 May; 24(5):606-20. PubMed ID: 15162895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus.
    Spoelstra JA; Stolk RP; Cohen D; Klungel OH; Erkens JA; Leufkens HG; Grobbee DE
    J Clin Psychiatry; 2004 May; 65(5):674-8. PubMed ID: 15163254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.